Youngchul Song
76 works · 10,472 citations · h-index 20
Top works
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- Combined targeting of HER2 and VEGFR2 for effective treatment of HER2 -amplified breast cancer brain metastases
- PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
- Activation of PI3K Signaling in Merkel Cell Carcinoma
- Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
- Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
- Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
- Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer
- Rectus Abdominis Muscle Endometriosis